Connect your AI

BioLife Solutions BLFS Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Thermo Fisher ScientificTMO

——

DanaherDHR

——

AzentaAZTA

——

LeMaitre VascularLMAT

——

TEC

Bio-TechneTECH

——

RevvityRVTY

——

Other financials

Income statement

Revenue$27.5M+24.7%

Gross profit$17.5M+18.2%

Operating income$27.0K+105%

Net income$1.2M+365%

EPS (diluted)$0.02—

Balance sheet

Cash & equivalents$22.8M-65.9%

Total debt$17.4M-35.6%

Total equity$372.2M+5.6%

Total assets$400.9M+1.5%

Cash flow

Operating cash flow-$491.0K-128%

CapEx$167.0K-4.6%

Free cash flow-$658.0K-142%

Valuation

Market cap$1.34B+33.1%

Enterprise value$1.34B+38.1%

P/S13.5×+0.6×

Profitability

Gross margin66.9%—

Operating margin-16.7%—

Net margin-68.7%—

FCF margin-15.9%+18.7pp

Returns & leverage

Return on equity-14.5%-4.7pp

Debt / equity0×0.0×

Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BioLife Solutions's software and technology licenses, net?: BioLife Solutions (BLFS) reported software and technology licenses, net of $3.05M in Q1 2026.